Jay Bradner’s NIBR exit sets off a succession plan at Merck; Dyne and MorphoSys fill major R&D roles

Jay Bradner

→ In the Big Pharma world, companies like J&J and Merck have experienced a pronounced sea change in leadership over a two-year period, and you can begin to say the same at Novartis, which dismissed head of development John Tsai and head of...

Click to view original post